LEWISVILLE, Texas / Mar 03, 2023 / Business Wire / Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will host an Analyst Teach-In Meeting in Lewisville, TX on Monday, March 13, 2023 from 2:30 - approximately 6:30 p.m. CT.
The event will feature presentations from the C-Suite management team and business unit leaders describing the product portfolio of the newly merged Orthofix-SeaSpine organization, including addressable market opportunity and commercial strategy.
Due to limited capacity, in-person attendance is by invitation only. A live and archived webcast of the event will be available on the Investors page of the company’s website at ir.Orthofix.com.
About the Combined Company:
The newly merged Orthofix-SeaSpine organization is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions and a leading surgical navigation system. Its products are distributed in approximately 68 countries worldwide.
The Company is headquartered in Lewisville, Texas and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics. The combined company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany, Paris, France and Sao Paulo, Brazil.
Last Trade: | US$13.48 |
Daily Change: | -0.19 -1.39 |
Daily Volume: | 172,072 |
Market Cap: | US$515.070M |
March 19, 2025 February 25, 2025 November 07, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load